Breast reconstruction with autologous fat combined with platelet rich plasma: fighting between medical novelty and cancer biology.
Syllaios A., Tsimpoukelis A., Vagios I., Kyros E., Davakis S.
Laboratory Study, published in J BUON (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J BUON (2019)
- Country
- Cyprus
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 31646801
Abstract (original English)
The use of autologous fat transplantation for reconstruction purposes after mastectomy or Breast Conserving Treatment (BCT) for Breast Cancer (BC) has increased significantly the past twenty years. Adipose-derived stemm cells hold great tissue regenerative potential due to their established ability to improve the healing process through in situ differentiation and secretion of paracrine factors. Platelet-rich Plasma (PRP), contains high levels of diverse human growth factors for stem cells proliferation and differentiation in the course of tissue regeneration, and it has recently been accepted by many as a highly promising method for tissue regeneration. The molecular mechanisms mediating this effect are unclear and still remain under investigation. Major disadvantages on the use of PRP are not reported. Promising results in enhancing the survival of grafted fat has been shown with PRP with the potential of affecting patient's oncological outcome when applied on tumor excision sites.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.